Vaccinia Capping Enzyme, GMP-Grade (GMP-VCS-VE101), DMF #038028
  • Description: Adds the 7-methylguanosine cap structure (m7Gppp, Cap0) to the 5' end of mRNA
  • Applications: RNA Modification
    Labeling 5' end of mRNA
  • Quality: FDA Drug Master Files # 038028
    Manufactured according to GMP guidelines
    Antibiotic-free and animal-free production
    Suitable for manufacturing of mRNA therapeutics and vaccines
  • Related Products:
    2'-O-Methyltransferase (#GMP-MEH-VE101)
Catalog #GMP-VCS-VE101
/
Size

Order now, ships by:

Product Description
 The 7-methylguanosine cap structure (m7Gppp, Cap0) is a specific feature in eukaryotic mRNA, which is required for mRNA stability, splicing, nuclear export, effective translation, and mRNA decay. Vaccinia Capping Enzyme, a heterodimer of D1 and D12 subunits, adding the Cap0 structure to the 5' end of the RNA. The D1 subunit comprises an N-terminal RNA triphosphatase (TPase), a guanylyltransferase (GTase), and a C-terminal guanine-N7-methyltransferase (MTase). The D12 subunit binds and stimulates the MTase.

NOTE: mRNA Cap 2'-O-Methyltransferase (Kactus #GMP-MEH-VE101) is required to generate Cap 1 structure that reduces cellular innate immune response when the RNA is used in vivo .

This product has been filed with the FDA Drug Master Files (DMF) and is assigned DMF #038028.
Applications
 RNA Modification
Labeling 5' end of mRNA
Concentration
 10U/µL
Unit Definition
 One unit is defined as the amount of enzyme required to incorporate 10 pmol of (α32P) GTP into an 80 nt transcript in 1 hour at 37°C.
Source
 Expressed in an E.coli strain carries the genes of the Vaccinia virus capping enzyme.
Biotinylated
 no
Quality Standards
 Activity (Capping modification and efficiency measurement): ≥ 10 kU/mL
Purity (SEC-HPLC): ≥ 95%
Residual Endonuclease: Negative
Residual Exonuclease: Negative
Residual DNase: Negative
Residual RNase: Negative
Residual Protease: Negative
Endotoxin: ≤ 10 EU/mL
Residual Host Cell DNA: ≤ 100 pg/mg
Residual Host Protein: ≤ 20 ng/mg
Residual Heavy Metal: ≤ 10 ppm
Bioburden: ≤ 1 CFU/10mL
Form
 Liquid
Shipping
 Shipped with blue ice
Stability And Storage
 -20±5°C for 24 months. Avoid repeated freeze-thaw cycles.
Figure 1. Analysis of mRNA capping efficiency using LC-MS.

Have more questions?

Check out our Frequently Asked Questions page for more details about product specifications, ordering, and shipments.

Contact Us

support@kactusbio.us

NOTE: mRNA Cap 2'-O-Methyltransferase (Kactus #GMP-MEH-VE101) is required to generate Cap 1 structure that reduces cellular innate immune response when the RNA is used in vivo .
Recently viewed